Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs ZURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAMP Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–3 Matrix Metrics)

CAMP Overall Winner 6-Pillar Tally: CAMP 4 – 1 ZURA (1 Tie) Matrix Metrics: CAMP 4 – 3 ZURA

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas ZURA carries 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 41.9/100 SELL), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile ZURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs ZURA
CAMP NASDAQ Head-to-Head Winner
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 30.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.3 · SMA20: $3.82 · SMA50: $3.84
ZURA NASDAQ
Zura Bio Limited Class A Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.01
-6.02% 1D
Market Cap $119.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.55β · 272% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 45.0 Fund 58.0 Flow 70.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.1%), weak momentum, RSI 25
RSI-14: 24.8 · SMA20: $2.98 · SMA50: $3.81

6-Pillar Scorecard Institutional Category Breakdown (CAMP 4 – 1 ZURA)

Columns: Metric · CAMP · ZURA
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 26.6x N/M
2. Growth & Scale CAMP
Revenue Growth (YoY) +138.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M N/A
Market Cap $238.5M $119.4M
3. Profitability & Quality ZURA
Gross Margin N/A N/A
Operating Margin -991.8% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.1% -63.2%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$82M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $1.84 Book/Sh · -63.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAMP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 0.2% (<1st %ile)
Put/Call OI Skew N/A 1.51x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (4) vs ZURA (3)
Institutional Metric CAMP ZURA Criterion Row Edge
Market Capitalization
Scale
$238.5M $119.4M Larger Scale CAMP
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+138.9% +0.0% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% 0.0% Higher Margin ZURA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.1% -63.2% Higher ROE ZURA
52-Week Range Position
Momentum
22% ($3–$8) 1% ($1–$7) Stronger Trend CAMP
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 0.55β · 272% Vol Lower Realized Risk CAMP
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 46.3 / 100 (HOLD) Higher Composite ZURA
Trailing 12M Revenue (USD)
Operating Scale
$5.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$82M ($1.84 Book/Sh · -63.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +99.16 pp
CAMP: +25.8% · ZURA: -73.36%
3M Horizon CAMP +67.57 pp
CAMP: -15.05% · ZURA: -82.62%
6M Horizon CAMP +69.74 pp
CAMP: -4.82% · ZURA: -74.56%
1Y Horizon CAMP +71.46 pp
CAMP: -3.66% · ZURA: -75.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAMP vs ZURA. Trailing 12-month operating profitability (CAMP -991.8% vs ZURA 0.0%) and valuation multiples (CAMP N/M vs ZURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M
ZURA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZURA BREAKDOWN
59d in phase · OBV DISTRIBUTION
Current IV 0.2%
IV Percentile <1st %ile
Put/Call OI Skew 1.51x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ZURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $119.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs ZURA Key Questions & Quantitative Answers

As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). CAMP carries a Unified Composite Score of 41.9/100 (SELL) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas ZURA carries 46.3/100 (HOLD) at $1.01 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 41.9/100 SELL), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY). Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.3); meanwhile ZURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with ZURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CAMP generates $5.3M in USD-normalized revenue versus N/A for ZURA. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZURA.

CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas ZURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus ZURA (-63.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, ZURA carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 1.51x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.55β · 272% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.